 NOVATO, Calif. and MOUNTAIN VIEW, Calif. and LONDON, Sept. 09, 2022 GLOBE NEWSWIRE -- Ultragenyx Pharmaceutical Inc. NASDAQ: RARE, Ultragenyx, a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases and Mereo BioPharma Group plc NASDAQ: MREO, Mereo, a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that additional data from Mereos Phase 2b ASTEROID study related to setrusumab UX143 and information on the Phase 23 Orbit study will be presented at the American Society for Bone and Mineral Research 2022 Annual Meeting ASBMR being held September 9-12, 2022, in Austin, Texas. Setrusumab is a monoclonal antibody in development for the treatment of Osteogenesis Imperfecta OI, a rare disease affecting approximately 60,000 individuals in the US and Europe. 